Affiliation:
1. I. HORBACHEVSKY TERNOPIL NATIONAL MEDICAL UNIVERSITY, TERNOPIL, UKRAINE
2. INTERNATIONAL RESEARCH AND INNOVATION IN MEDICINE PROGRAM, CEDARS-SINAI MEDICAL CENTER, LOS ANGELES, CA, USA
3. SUMY STATE UNIVERSITY, SUMY, UKRAINE
Abstract
Aim of our research was to conduct a clinical and laboratory analysis of the impact of COVID-19 on pregnancy and the condition of the fetus.
Materials and Methods: At the first stage, we conducted a retrospective examination of 50 pregnant women treated at Ternopil Municipal Hospital No.2 (Ukraine) between November 2020 and January 2022 with the history of COVID-19, confirmed by PCR test, and 25 pregnant COVID-19 negative pregnant women (control group). At the second stage, we performed prospective cohort study and involved 40 pregnant women treated with the history of COVID-19, confirmed by PCR, and 10 pregnant COVID-19 negative women with a physiological course of pregnancy as a control group.Women were divided into the following groups: group I -10 women diagnosed with COVID-19 during the first trimester of pregnancy: group II-15 women diagnosed during the second trimester; group III-15 women diagnosed during the third trimester. Ultrasound examination and cardiotocograms were performed to assess fetus status. Blood samples were collected at delivery. To determine whether COVID-19 could alter placental angiogenesis, vascular endothelial growth factor A (VEGFA), PlGF and interleuin-32-α were assessed.
Results: We identified that concentration of VEGFA was 95.30±5.65 pg/ml in control group. In women who had COVID-19 in first trimester, this index was 1.3 times higher, in second trimester 1.63 times higher and in third trimester by 2 times compared to control group. PlGF concentration was only 27,4 percent in group I, 16 percent in group II and 30 percent in group III,compared to control group. Concentration of interleuin-32-α was 67.27±5.63 pg/ml in control group and increased to 167 percent in group I, by 2.8 times in group II and by 6.3 times in group III compared to control group.
Conclusions: COVID-19 has a negative impact on placental angiogenesis, including VEGFA and PlGF. Fetal post-COVID-19 syndrome requires timely diagnosis of disorders and further study. Post-COVID-19 syndrome is an immune-dependent pathology in which the processes of protracted cytokine activation occur in the body of a pregnant woman.
Reference29 articles.
1. 1. Blitz MJ, Gerber RP, et al. Preterm birth among women with and without severe acute respiratory syndrome coronavirus 2 infection. Acta Obstetricia et Gynecologica Scandinavica, 2021; 100(12):2253-2259.
2. 2. Di Toro F, Gjoka M, Di Lorenzo G, et al. Impact of COVID-19 on maternal and neonatal outcomes: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):36-46.
3. 3. Einarsdóttir K, Swift EM, Zoega H. Changes in obstetric interventions and preterm birth during COVID-19: A nationwide study from Iceland . Acta Obstetricia et Gynecologica Scandinavica, 2021;100(10):1924-1930.
4. 4. Facciolà A, Micali C, Visalli G, et al. COVID-19 and pregnancy: clinical outcomes and scientific evidence about vaccination. Eur Rev Med Pharmacol Sci. 2022;26(7):2610-2626.
5. 5. Boychuk AV, Budnyk TA, Boyarchuk OR. Provision of pregnant women with vitamin D and its influence on anthropometric indicators of the newborn. Voprosu pitania. 2020;89(5):80-88.